Korea Union Pharmaceutical, COVID-19 (Plasma Therapy/Plasma Therapeutics) Theme Rises 16.75%

On the 12th, the COVID-19 (plasma treatment/plasma therapy) theme showed strength by rising 3.01% compared to the previous day, while Korea Union Pharmaceutical, gaining attention as a related stock, surged 16.75% compared to the previous day. Korea Union Pharmaceutical is known as a manufacturer of prescription drugs.

[Graph] Major stock price changes in the COVID-19 (plasma treatment/plasma therapy) theme

According to the analysis by Thinkpool Robo Algorithm RASSI, Korea Union Pharmaceutical’s quant financial score is 11.6 points, which is lower in stability, profitability, and growth compared to the average of other stocks related to COVID-19 (plasma treatment/plasma therapy). This can be interpreted as Korea Union Pharmaceutical having relatively low investment attractiveness compared to other stocks from a financial perspective. On the other hand, SMAC ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of the Robo Algorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, and other factors.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.